Without access to easy to use analysis tools, patents are becoming an expensive hindrance to many small companies, says Mick McLean, Head of Economics and Public Policy at Scientific Generics.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.